Active surveillance versus treatment in low-risk DCIS: Women’s preferences in the LORD-trial
Renée Schmitz(The Netherlands Cancer Institute), Eveline M. A. Bleiker(Leiden University Medical Center), Jelle Wesseling(Leiden University Medical Center), Julia Houtzager(The Netherlands Cancer Institute), Ritse M. Mann(Radboud University Nijmegen), Miranda A. Gerritsma(The Netherlands Cancer Institute), Ellen Verschuur(Borstkankervereniging Nederland), Frederieke van Duijnhoven(The Netherlands Cancer Institute), Rosalie Griffioen(The Netherlands Cancer Institute), Valesca P. Retèl(The Netherlands Cancer Institute), Ellen G. Engelhardt(The Netherlands Cancer Institute), Carine Sondermeijer(Amsterdam UMC Location University of Amsterdam), Nina Bijker(Amsterdam University Medical Centers)
Cited by 39
Related Papers
Efficacy of Radiofrequency Ablation Combined With Endoscopic Resection for Barrett's Esophagus With Early Neoplasia
|Clinical Gastroenterology and Hepatology|2009|313
Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer Subtype
|Journal of Clinical Oncology|2011|306
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
|The Lancet Oncology|2007|278
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
|Breast Cancer Research and Treatment|2009|256
Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
|British Journal of Cancer|2013|241